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Introduction: Rapid scale-up of antiretroviral therapy rollout in Sub-Saharan African countries faces the challenge of
virological failure. This could be the consequence of transmitted drug-resistant human immunodeficiency virus
strains at the population level. While a pre-antiretroviral therapy genotypic test has been a major component of the
human immunodeficiency virus management programme in developed nations, it is yet to be incorporated into
the antiretroviral therapy programme in resource-poor countries.
Case presentation: A 32-year-old Black African woman was seen for her six-month routine review. Her viral load
after initiation of fixed drug combination of tenofovir, emtricitabine and efavirenz was 31,397 RNA copies/mL.
Adherence was assessed to be good based on pharmacy pick-up dates, on-time clinic appointment records,
medical file review, self-reporting and treatment supporter’s report. Her viral load was repeated after another two
months of close monitoring; the result showed viral load of 31,159 RNA copies/mL. She was assessed as virological
failure to her first-line antiretrovirals and commenced on second-line antiretrovirals: zidovudine/lamivudine/Aluvia®
(lopinavir and ritonavir). A human immunodeficiency virus drug genotypic testing showed she was only susceptible
to zidovudine and protease inhibitors. At third month on the new regimen, her viral load was suppressed.
Conclusions: This case report demonstrates the possibility of a silent epidemic within the human
immunodeficiency virus pandemic in resource-poor settings like Eastern Cape, South Africa. We described a case of
early virological failure in a highly motivated young woman. Although, a pre-antiretroviral therapy genotypic test is
yet to be incorporated into a human immunodeficiency virus programme in resource-poor countries, the need for
it might become evident as the programme expands. Close monitoring of the viral load of patients according to
national guidelines will enable early detection of a failing regimen and prompt intervention can be instituted to
prevent morbidity and mortality. There is an urgent need to strengthen the human immunodeficiency virus
programme in resource-poor countries to prevent the emergence of an epidemic of transmitted drug-resistant
human immunodeficiency virus strains within the existing human immunodeficiency virus pandemic.
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According to the 2013 Global Report of the Joint United
Nations Programme on HIV and AIDS (UNAIDS), 35.3
million people were living with human immunodefi-
ciency virus (HIV) by the end of 2012 and 70.8% of the
global burden reside in Sub-Saharan Africa. South Africa* Correspondence: dudumela@yahoo.com
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unless otherwise stated.has the highest burden of the HIV epidemic (6.4 million
people living with HIV/acquired immunodeficiency syn-
drome) [1]. The global response to the epidemic has
seen more than 60% of eligible individuals already initi-
ated on antiretroviral therapy (ART) using World Health
Organization (WHO) criteria of 2010 (CD4 count ≤350
cells/mL) and approximately 34% using WHO 2013 cri-
teria (CD4 count ≤500 cells/mL) [2].
The impact of the scale-up of ART includes 4.2 mil-
lion deaths averted, 800,000 child infections averted with
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fections in 2012 [2]. The probable challenges of rapid
scale-up of ART include loss to follow up, virological
failures and drug resistance (acquired and transmitted).
These have not been fully investigated in resource-poor
settings; however, their possibility has been documented
[3]. While acquired resistance has received attention in
the national programmes of most resource-poor coun-
tries of Sub-Saharan Africa [4], transmitted resistance
has not received similar attention.
This is the first case report to the best of our knowledge
to describe a patient who experienced a primary virological
failure possibly secondary to transmitted drug-resistant
HIV (TDRHIV) strain in Eastern Cape, South Africa.
Case presentation
Six months ago, a 32-year-old Black African woman was
seen for her routine review. She was asymptomatic. Ap-
proximately 13 to 14 months earlier, she was referred to
our HIV Unit because of a low CD4 count for ART initi-
ation. She was antiretroviral (ARV)-naïve with WHO
clinical stage 3 (oral candidiasis) and a baseline CD4
count of 14 cells/mL. Reflex laboratory serum Crypto-
coccal Latex Antigen Test serology was negative. The re-
sults of other baseline investigations were within normal
limits. Her symptom screen for tuberculosis was nega-
tive. Alcohol and substance use were excluded. There
was no history of depression or any comorbid chronic
illnesses. She disclosed her status to her partner. She
was nulliparous.
Her medications during preparation for ARVs included
co-trimoxazole, multivitamins and oral nystatin. She was
commenced on a fixed dose combination of tenofovir,
emtricitabine and efavirenz daily (according to the South
African National Department of Health Guideline, 2013)
[4]. She was followed up at 2, 4 and 8 weeks for immune
reconstitution inflammatory syndrome and adverse ef-
fects. At each visit, adherence was reviewed and further
counselling was provided. Isoniazid prophylaxis was ini-
tiated; her estimated glomerular filtration rate was nor-
mal at three months (glomerular filtration rate >60 mL/
minute/1.73m2).Table 1 Mutation score of patient
RT 3TC ABC AZT D4T DDI
K65R 30 45 −15 45 60
M184I 60 15 −10 −10 10
K103S − − − − −
V106M − − − − −
M230L − − − − −
K653+M184I − − − 10 −
Abbreviations: 3TC lamivudine, ABC abacavir, AZT zidovudine, D4T stavudine, DDI did
RPV rilpivirine, RT reverse transcriptase, TDF tenofovir.She was again reviewed at six months in 2014: viral
load (VL) of 31,397 ribonucleic acid (RNA) copies/mL; a
log value of 4 was obtained. Poor adherence was consid-
ered despite her and the treatment supporter’s account
of good adherence. A thorough evaluation of the medical
files for clinic attendance, pharmacy records for pick-up
of medications and pill count charts was conducted. She
was deemed to have a relatively good adherence. There
were no drug–drug interactions; no herbal or alternative
therapies were used during the period of treatment. She
was not treated for diarrhoea or vomiting during the
preceding 6 months. Further questions about her new
sexual partner and HIV status of previous sexual part-
ners did not yield any new information and she had not
been sexually active since diagnosis of HIV. Adherence
was consolidated for another two months with intense
monthly review. Her VL at eight month remained 31,159
RNA copies/mL in spite of excellent adherence. We con-
firmed virological failure. An assessment of a probable pri-
mary virological failure from TDRHIV was considered. A
decision was made to switch to a second-line regimen of
zidovudine (AZT)/lamivudine/lopinavir and ritonavir at
standard doses.
After analysing the case we decided to do an HIV drug
genotypic test outside the National guideline to under-
stand the pattern of resistant mutation in our patient.
The genotypic test result showed susceptibility to pro-
tease inhibitors and AZT (Table 1).
The HIV subtype isolated in the genotypic testing was
subtype C. The K65R mutation was noted as part of the
nucleoside/nucleotide reverse-transcriptase inhibitor mu-
tation; however, AZT remains active.
She was reviewed monthly and a blood sample for VL
was taken at third month of commencing second-line
ARVs. The result confirmed viral suppression (VL=25
RNA copies/mL). She is presently doing well.
The timeline of the case is shown in Figure 1.
Discussion
The case report suggests the possibility of yet another
epidemic that may be emanating from the HIV pan-
demic; awareness of its existence is a reality in resource-FTC TDF EFV ETR NVP RPV
30 60 − − − −
60 −10 − − − −
− − 45 0 60 0
− − 60 0 60 0
− − 45 30 60 45
− 10 − − − −
anosine, EFV efavirenz, ETR etravirine, FTC emtricitabine, NVP nevirapine,
Figure 1 Timeline of important clinical events during management of patient. Abbreviations: 3TC, lamivudine; ARV, antiretroviral; AZT, zidovudine;
EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; RNA, ribonucleic acid; TDF, tenofovir; VL, viral load; WHO, World Health
Organization. Aluvia® is lopinavir and ritonavir.
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the rising prevalence of TDRHIV remains uncertain. A
pre-ART genotypic test is a prerequisite for initiation of
treatment in resource-rich nations [5], whereas a geno-
typic test is reserved for second-line regimen failures in
resource-constrained settings like ours [4,6,7]. The dif-
ference between the two models of HIV care could result
in a minimum of ≥eight months’ delay in initiating ef-
fective ART in patients with TDRHIV which was the
case in this patient.
The two VLs taken according to the South African
ART guideline [4] confirmed virological failure. What
remains applicable in our practice setting is the role of
VL monitoring, which was adhered to strictly in our pa-
tient. Hence, VL monitoring may remain the only tool
to determine early ARV failure in the resource-poor set-
ting where we practice. However, it is worth noting that
TDRHIV is one of the documented causes of virological
failure on a first-line regimen [8] which is a possibility
in this patient. Safe sexual practice should be advocated
in all patients to prevent the spread of TDRHIV strainsat a community level [9,10]. Of importance in our pa-
tient is her being ARV naïve with no past obstetrics
history.
Similar to a meta-analysis conducted by Gupta et al.,
our patient has acquired many mutations (Table 1) [11].
However, we found that she remained susceptible to
AZT as mutations found in combination with K65R in
our case enhance susceptibility to AZT (M184V as well
as K65R) [12]. Therefore, we expect that AZT would re-
main active against such viruses. The latest VL of 25
RNA copies/mL from her confirmed an effective ART
after an initial delay of 8 months.Limitations of current practice
It remains a challenge that a pre-ART genotypic resist-
ance testing could not be undertaken in patients with
HIV infection in a resource-constrained setting as this
would have provided information on the baseline ARV
drug resistance. Also, the inability to conduct ARV drug
levels in the partner of the patient should be noted.
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Although, a pre-ART genotypic test is yet to be incorpo-
rated into an HIV programme in resource-poor coun-
tries, the need for its incorporation into clinical care
may become more evident as the prevalence of TDR
rises. Meanwhile, close monitoring of VL of patients ac-
cording to the national guidelines is very important. This
will enable early detection of a failing regimen and
prompt intervention can be instituted to prevent accu-
mulation of resistant strains, virological failure, morbid-
ity and mortality. There is an urgent need to strengthen
the HIV programme in resource-poor settings to prevent
the emergence of a silent epidemic of TDRHIV within
the HIV pandemic.
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